Karthik Sriram | Biotech Finance, Peptide Therapeutics, and Strategic Growth
Karthik Sriram joins Executive Insights for Life Sciences Innovators to discuss biotech finance, peptide therapeutics, strategic decision-making, and the operational discipline required to scale clinical-stage life sciences organizations.
Prefer audio only? Listen to this episode on Spotify.
Episode Overview
In this episode, Karthik Sriram discusses how Parabilis Medicines is advancing next-generation peptide therapeutics through its Helicon™ platform. The conversation explores the role of financial planning and analysis in biotech, strategic resource allocation, platform development, and the challenges of scaling a clinical-stage organization in an evolving market environment.
Key Themes
- Next-generation peptide therapeutics
- Financial planning and analysis in biotechnology
- Strategic decision-making in clinical-stage companies
- Platform-based drug development and portfolio management
- Scaling life sciences organizations
- The future of peptide therapeutics and biotech innovation
Why This Matters for Life Sciences Leaders
Successful biotechnology companies require more than scientific innovation. They depend on disciplined capital allocation, strategic planning, and the ability to align financial and operational decisions with long-term development goals. The conversation highlights how finance leaders contribute to company strategy, support platform growth, and help organizations navigate the complexities of advancing novel therapies in competitive markets.
Guest Link
More from Executive Insights
Explore more conversations with life sciences founders, CEOs, investors, and operators on the Executive Insights for Life Sciences Innovators podcast.
